Possible increased risk of leg and foot amputations with canagliflozinU.S. and European authorities issue safety announcement and continue to investigate. New diabetes treatment linked to red grapes and oranges Depression + metabolic risk factors boost chances of Type 2 diabetes Adding a DPP-4 inhibitor to sulfonylurea therapy increases hypoglycemia risk by 50% Sulfonylurea dose should be reduced when starting a DPP-4 inhibitor in type 2 diabetes. Updated Canadian diabetes guidelines for pharmacologic management of type 2 diabetes Empagliflozin should be added when glycemic targets are not met in patients with clinical cardiovascular disease. CE Lesson: Type 2 Diabetes Individualizing drug therapy in T2D. VIDEO: Gender-specific issues in diabetes A diabetes network for pharmacists Getting the real scoop on sugar Reversing diabetes for good? First Previous 34 35 36 37 38 Next Last
